Diamonds and Dogs


Juno is jumping. Biotech, Juno Therapeutics (JUNO) is up 26% today after jumping 55% last week on now confirmed rumors that Celgene will acquire them to for $9 billion, or $87 a share in cash. Celgene said the deal, expected to close in the first quarter of this year, should add 50 cents a share to adjusted per-share earnings in 2018. Juno's JCAR017 treatment for non-Hodgkin lymphoma should "be a significant growth driver beyond 2020 with potential global peak sales of approximately $3 billion. Celgene has been looking to add to their pipeline after a promising drug was discontinued last year. Celgene's stock is unchanged, but down 30% in the last four months.

PetMed Express (PETS) initially soared 8% this morning before sinking into the red following earnings. PetsMed reported net income of 44 cents per share, growing 83% year over year and beating estimates of 32 cents. Sales rose nearly 14% to $60.1 million and topped expectations for $56.7 million. PetMed also increased its quarterly dividend to 25 cents per share, but unfortunately, shareholders are in the selling mood.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.